PDS Biotechnology Corporation (PDSB) Bundle
A Brief History of PDS Biotechnology Corporation (PDSB)
Foundation and Initial Developments
PDS Biotechnology Corporation was founded in 2006. The company is primarily engaged in the development of innovative cancer immunotherapy products based on its proprietary technology. PDSB is headquartered in New Brunswick, New Jersey.
Public Offering and Financial Milestones
PDSB went public on the NASDAQ under the ticker symbol PDSB in 2017. The initial public offering (IPO) raised approximately $10 million. In 2020, the company reported revenues of $3.1 million, showcasing a growth trajectory in its financial performance.
Partnerships and Collaborations
PDS Biotechnology has entered into various partnerships to enhance its research and development capabilities. Significant collaborations include:
- Agreement with the National Cancer Institute (NCI) to facilitate clinical trials.
- Partnership with Merck & Co. to develop combination therapies.
- Collaboration with various academic institutions for ongoing research.
Key Product Development: PDS0101
PDS0101 is the company’s lead product candidate, an investigational immunotherapy designed to treat HPV-associated cancers. In 2021, PDSB announced a successful Phase 2 clinical trial, reporting a 78% overall response rate in patients.
Recent Financial Data
As of Q2 2023, PDS Biotechnology Corporation reported cash and cash equivalents amounting to approximately $34.2 million. The company had a total revenue of $4.1 million for the fiscal year ending 2022, demonstrating a year-over-year increase.
Stock Performance
As of October 2023, the stock price of PDS Biotechnology Corporation fluctuated around $2.50 per share. The market capitalization was approximately $33 million, reflecting the company’s position in the biotech sector.
Table of Financial Performance
| Year | Revenue (in Millions USD) | Net Income (in Millions USD) | Cash and Equivalents (in Millions USD) | Market Capitalization (in Millions USD) |
|---|---|---|---|---|
| 2020 | 3.1 | -9.2 | 20.5 | 45 |
| 2021 | 2.5 | -6.8 | 25.9 | 60 |
| 2022 | 4.1 | -10.3 | 29.8 | 38 |
| 2023 (Q2) | N/A | N/A | 34.2 | 33 |
Future Directions
PDS Biotechnology Corporation aims to advance its pipeline products through continued clinical trials and regulatory approvals. The company is focused on expanding its therapeutic applications beyond HPV-related cancers.
A Who Owns PDS Biotechnology Corporation (PDSB)
Shareholder Composition
Shareholder Composition
As of the latest data, PDS Biotechnology Corporation (PDSB) has a diverse shareholder base comprising institutional investors, retail investors, and company insiders. Below is a breakdown of the ownership structure:
| Ownership Type | Percentage of Shares Owned | Number of Shares Owned |
|---|---|---|
| Institutional Investors | 45% | 10,500,000 |
| Retail Investors | 35% | 8,200,000 |
| Company Insiders | 20% | 4,500,000 |
Major Institutional Shareholders
Several institutional investors hold significant stakes in PDSB. The following table lists the major institutional shareholders as of the most recent report:
| Institution | Shares Owned | Percentage of Ownership |
|---|---|---|
| BlackRock, Inc. | 2,000,000 | 8.5% |
| Vanguard Group, Inc. | 1,800,000 | 7.6% |
| State Street Corporation | 1,500,000 | 6.4% |
| Goldman Sachs Group, Inc. | 1,200,000 | 5.1% |
Insider Ownership
Insider ownership is a critical indicator of a company's alignment between management and shareholder interests. Below is a list of significant company insiders and their respective ownership stakes:
| Name | Position | Shares Owned | Percentage of Ownership |
|---|---|---|---|
| Dr. Frank Bedu-Addo | CEO | 1,000,000 | 4.2% |
| Mr. Paul D. Pomerantz | Chairman | 900,000 | 3.8% |
| Ms. Lisa C. Sun | CFO | 700,000 | 3.0% |
Recent Stock Performance
PDS Biotechnology's stock (PDSB) has seen various changes in its valuation over recent months. The following are key financial metrics:
| Date | Stock Price (USD) | Market Capitalization (USD) |
|---|---|---|
| October 2023 | 2.25 | 51,750,000 |
| September 2023 | 2.50 | 57,000,000 |
| August 2023 | 3.10 | 70,800,000 |
Recent Financial Performance
Here are the latest financial results for PDS Biotechnology Corporation (PDSB):
| Financial Metric | Value (USD) |
|---|---|
| Total Revenue (2022) | 5,000,000 |
| Net Loss (2022) | (15,000,000) |
| Total Assets (as of Q2 2023) | 30,000,000 |
| Total Liabilities (as of Q2 2023) | 10,000,000 |
PDS Biotechnology Corporation (PDSB) Mission Statement
Company Overview
PDS Biotechnology Corporation (PDSB) is a clinical-stage biotechnology company focused on transforming cancer treatment through the development of immunotherapies, particularly its proprietary PDS0203 and PDS0101 therapies.
Core Mission
The mission of PDS Biotechnology Corporation is to develop innovative immunotherapies that harness the body's immune system to combat cancer effectively and safely. The company aims to provide solutions that improve patient survival rates and quality of life.
Vision Statement
PDSB envisions becoming a leader in the field of immuno-oncology by delivering ground-breaking therapies that enhance the body's immune response to cancers. This vision is reflected in their commitment to research, clinical trials, and partnerships with leading medical institutions.
Strategic Objectives
- Advance clinical trials for PDS0101 and PDS0203 to determine their efficacy and safety.
- Enhance collaborations with healthcare professionals and research institutions.
- Expand product pipeline to include additional therapies targeting various cancers.
- Achieve regulatory approvals in key markets for their immunotherapy products.
Financial Overview
As of the latest report in Q3 2023, PDS Biotechnology Corporation reported the following financial metrics:
| Financial Metric | Q3 2023 Amount | Q2 2023 Amount | Q1 2023 Amount |
|---|---|---|---|
| Revenue | $2.1 million | $1.5 million | $1.0 million |
| Net Loss | ($8.3 million) | ($7.2 million) | ($6.5 million) |
| Cash and Cash Equivalents | $25.6 million | $30.0 million | $37.0 million |
| Market Capitalization | $150 million | $120 million | $100 million |
Research and Development Focus
PDSB's mission is supported by their strong emphasis on research and development, particularly in the following areas:
- Development of the Versamune® platform for enhancing T cell responses.
- Exploration of combination therapies with checkpoint inhibitors.
- Targeting various types of cancer, including HPV-associated cancers.
Commitment to Patients
The company emphasizes a patient-centric approach, aiming to deliver therapies that address unmet medical needs in oncology. PDSB is dedicated to:
- Improving clinical outcomes for patients with advanced cancer.
- Reducing the side effects associated with traditional cancer treatments.
- Providing hope through innovative treatment options.
Partnerships and Collaborations
PDS Biotechnology Corporation actively seeks strategic partnerships to enhance its mission, including:
- Collaborations with academic institutions for research support.
- Agreements with biotech firms for shared technology development.
- Partnerships with healthcare providers for clinical trial execution.
Conclusion Metrics
In summary, PDS Biotechnology Corporation's mission is reflected through its commitment to innovation, clinical success, and partnerships in the field of immunotherapy. The reported financials and strategic objectives highlight their ongoing progress and dedication to improving cancer treatment outcomes.
How PDS Biotechnology Corporation (PDSB) Works
Core Technology and Platform
PDS Biotechnology Corporation utilizes a proprietary platform known as the Versamune® technology, which is designed to enhance the immune response to cancer and infectious diseases. This platform aims to deliver antigens in a way that maximizes the activation of dendritic cells and T cells, making the immune response more robust.
Product Pipeline
The main products being developed by PDSB include:
- PDS0101 - A therapeutic cancer vaccine targeting human papillomavirus (HPV)-associated cancers.
- PDS0203 - A vaccine candidate for the treatment of head and neck cancers.
- PDS0501 - A vaccine candidate for various types of solid tumors.
| Product Candidate | Indication | Phase of Development | Expected Milestone |
|---|---|---|---|
| PDS0101 | HPV-associated cancers | Phase 2 | Interim data release in Q4 2023 |
| PDS0203 | Head and neck cancers | Phase 1/2 | Initial data release in Q1 2024 |
| PDS0501 | Solid tumors | Preclinical | IND filing expected by Q2 2024 |
Financial Overview
As of the third quarter of 2023, PDSB reported the following financial highlights:
- Cash and Cash Equivalents: $26.5 million
- Total Revenue: $0.9 million
- Net Loss: $6.2 million
The company projects its operating expenses for 2024 to be between $25 million and $30 million.
Funding and Partnerships
PDS Biotechnology Corporation has secured funding through various avenues, including:
- Public Offerings: Gross proceeds of approximately $15 million raised in a registered direct offering in June 2023.
- Collaborations: Partnerships with academic institutions for research and clinical trials.
| Funding Source | Amount Raised | Date |
|---|---|---|
| Public Offering | $15 million | June 2023 |
| Grant from NIH | $2.5 million | March 2023 |
Market Position and Strategy
PDS Biotechnology Corporation focuses on the advanced development of its immunotherapy candidates. The competitive landscape includes other biotech companies involved in immuno-oncology, such as:
- Moderna, Inc.
- Adaptimmune Therapeutics PLC
- Immunovant, Inc.
The company aims to leverage its unique technology to carve out a strong niche in the immuno-oncology market, estimated to be valued at $168 billion by 2026.
Clinical Trials and Regulatory Pathways
PDSB is actively engaged in multiple clinical trials:
- Phase 2 trial for PDS0101: Expected to enroll 150 patients across multiple sites.
- Fast Track Designation: Received from the FDA for PDS0101.
| Trial Name | Indication | Status | Enrollment Size |
|---|---|---|---|
| PDS0101-001 | HPV-associated cancers | Ongoing | 150 patients |
| PDS0203-001 | Head and neck cancers | Ongoing | 75 patients |
Future Outlook
The company aims to further advance its clinical trials and expects to submit additional regulatory filings. PDSB's vision aligns with the growing demand for immunotherapeutic options in cancer treatment, supporting its strategic objectives.
How PDS Biotechnology Corporation (PDSB) Makes Money
Revenue Generation Through Clinical Development
PDS Biotechnology Corporation focuses on developing innovative therapeutic options, primarily through its proprietary Versamune® platform. This platform is designed to enhance the immune response to tumor-associated antigens. The company has several clinical trials ongoing, involving potential revenue generation from collaborations, grants, and investments.
Collaborations and Partnerships
PDSB has established collaborations with various pharmaceutical companies and research institutions. Such partnerships often involve milestone payments and royalties.
| Partner | Type of Collaboration | Financial Terms |
|---|---|---|
| Merck & Co. | Research Collaboration | Undisclosed milestone payments up to $100 million |
| National Institutes of Health (NIH) | Grant Funding | $4.1 million awarded for clinical trial support |
| U.S. Department of Defense | Research Grant | $2 million for the development of cancer immunotherapies |
Potential Revenue from Product Candidates
The company has multiple product candidates in various stages of clinical trials that may lead to significant income upon commercialization.
| Product Candidate | Indication | Stage | Projected Market Size (USD) |
|---|---|---|---|
| PDS0101 | HPV-associated cancers | Phase 2 | $1.5 billion |
| PDS0202 | Head and neck cancers | Phase 1 | $1 billion |
| PDS0301 | Acute Myeloid Leukemia (AML) | Preclinical | $450 million |
Stock Offering and Financing
PDSB has engaged in various financing activities, including public offerings and private placements to fund its operations. Recent data indicates:
| Type of Offering | Date | Amount Raised (USD) |
|---|---|---|
| Public Offering | February 2023 | $15 million |
| Private Placement | March 2023 | $10 million |
Revenue from Licensing Agreements
PDSB also seeks to generate revenue through licensing agreements with other biotechnology companies. These agreements allow partners to utilize PDSB's proprietary technologies in their own product development efforts.
- Licensing agreements can yield upfront payments, milestone payments, and royalties on sales.
- The company has previously reported licensing deals that can exceed $50 million per agreement, depending on the scope and potential of the technology.
Grants and Government Funding
PDS Biotechnology has received numerous grants aimed at fostering innovative medical research.
- In addition to the NIH and DOD grants mentioned earlier, PDSB has pursued various foundations and non-profit grants.
- The cumulative total of government-related funding can exceed $10 million annually, depending on active projects.
Future Financial Outlook
The financial outlook for PDSB will largely depend on the success of its clinical trials and the ability to secure additional partnerships. Key determinants include:
- Current Phase 2 trial results for PDS0101 are set to release in Q4 2023.
- Existing cash as of Q2 2023 stands at approximately $30 million, providing a runway for ongoing clinical development.
Market Potential and Competitive Landscape
The overall market for cancer immunotherapies is projected to exceed $100 billion globally by 2025.
- PDSB's unique approach may position it favorably against established competitors like Bristol-Myers Squibb and Merck.
- As of October 2023, revenue forecasts suggest that successful commercialization of PDSB products could capture a significant share of emerging therapy markets.
PDS Biotechnology Corporation (PDSB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support